Navigation Links
Microarray technology for tailoring breast cancer therapy

Microarray technology could be used to tailor therapy according to the individual, and prevent breast cancer patients from having to undergo painful unsuccessful therapies. In a study published in the journal Breast Cancer Research, researchers analysed tumour tissue samples and identified a group of64 genes that can be used to predict a patient's response in the five years after adjuvant therapy for breast cancer. Identifying patients whose breast tumours express these genes could potentially be used to predict which patients would not benefit from adjuvant therapy, and avoid patients being given therapies with the potential of causing more harm than good.

A team of researchers led by Jonas Bergh from the Karolinska Institutet in Stockholm, Sweden, analysed the gene expression profiles of 159 breast cancer patients using DNA microarray analysis. From these samples they identified the genetic signatures shown by 38 patients who had a poor prognosis - defined as relapse or death from any cause within 5 years. The remaining 121 patients were defined as the 'good prognosis' group. The researchers also used gene expression profiling to separate patients who did well with and without adjuvant therapy, and those whose tumours failed to respond to treatment.

An analysis of the genes expressed in the tumours of all 159 patients showed that 64 genes were used to separate the patients with good and poor prognoses.The researchers then tested the predictive value of the group of 64 genes compared with three currently used clinical markers. Using the expression patterns of the 64 genes identified by the researchers gave significantly better(P=0.007) prediction rates than histological grading, tumour stage and age - which are all accepted prognostic markers for breast cancer.

The present lack of criteria to help tailor breast cancer treatment to individual patients indicates a need to develop new techniques for better prediction of how patients will respond to adjuvant treatments. The researchers suggest that the technique of DNA microarray analysis could be developed to help breast cancer patients who do not benefit from adjuvant therapy, and avoid painful unnecessary treatments and wastage of healthcare resources.


Source:Karolinska Institutet

Related biology news :

1. Affymetrix Unveils Plans to Double Plant and Animal Genome Microarray Offering
2. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
3. Breakthrough Microarray-based Technology for the Study of Cancer
4. Nanogen Issued Patent for Electronic Microarray With Memory
5. Characterizing Skin Cancer by Microarrays
6. Microarrays as phenotype
7. $6.5 Million Grant for Microarray Center at Yale School of Medicine
8. Agilent Technologies Introduces First Commercial Mouse Microarray for Comparative Genomic Hybridization Research
9. Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible?status
10. Novel technology detects human DNA mutations
11. Novel antiviral technology inhibits RSV infection in mice
Post Your Comments:

(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , an ... of clinical research, is pleased to announce that it will ... Trials (PCT) event, to be held November 17-19 in ... to view live demonstrations of iMedNet , ... how iMedNet has been able to deliver time ...
(Date:11/10/2015)... , Nov. 10, 2015 ... behavioral biometrics that helps to identify and verify ... Signature is considered as the secure and accurate ... identification of a particular individual because each individual,s ... accurate results especially when dynamic signature of an ...
(Date:11/9/2015)... , Nov. 9, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced broader entry into the automotive market ... that match the pace of consumer electronics human interface ... sensors are ideal for the automotive industry and will ... Europe , Japan ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... 24, 2015  Asia-Pacific (APAC) holds the third-largest ... market. The trend of outsourcing to low-cost locations ... higher volume share for the region in the ... margins in the CRO industry will improve. ... ( ), finds that the market earned ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" ... reported financial results for the quarter ended September ... in Canadian dollars and presented under International Financial ... States ," said Andrew Rae , ... regarding iCo-008 are not only value enriching for ...
(Date:11/24/2015)... -- Clintrax Global, Inc., a worldwide provider of clinical research services headquartered ... the company has set a new quarterly earnings record in Q3 ... posted for Q3 of 2014 to Q3 of 2015.   ... , with the establishment of an Asia-Pacific ... United Kingdom and Mexico , with ...
(Date:11/24/2015)... SHPG ) announced today that Jeff Poulton , Chief ... Annual Healthcare Conference in New York City , ... p.m. GMT). --> SHPG ) announced today that ... Jaffray 27 th Annual Healthcare Conference in New ... 8:30 a.m. EST (1:30 p.m. GMT). --> Shire plc ...
Breaking Biology Technology: